Executive Director, Chief Quality and Regulatory Officer at Aegros Innovations
At Aegros we believe, access to life saving therapeutic plasma drugs is a human right and not a privilege. Our mission is to put the Patient 1st through the application of our unique ElectroSeparation process. Our Plasma Fractionation plant is in Macquarie Park and is currently being fitted out to manufacture a hyperimmune from Convalescent Covid-19 plasma called CovimmuneTM. Aegros will begin clinical trials in association with a Sydney major trauma hospital in October 2020.Covimmune: a hyperimmune to provide protection against Covid-19 for Front Line Healthcare Workers.